We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dye-Dendrimer Complexes Show Enhanced Fluorescence

By HospiMedica staff writers
Posted on 16 May 2007
Dye-dendrimer complexes have been created from various commercial dyes that show enhanced fluorescent (greater than 10-fold) and photostability (greater than four-fold), in addition to improved solubility in water.

Fluorescent reagents are used extensively in laboratories for diagnostic immunoassays, high-throughput screening, microarrays, fluorescence microscopy, genomics, and proteomics.

Starpharma (Melbourne, Australia), through its U.S. More...
subsidiary company Dendritic Nanotechnologies, Inc. (DNT), has found that DNT's Priostar dendrimer technology can be used to amplify the signal and increase the duration of the signal (photostability) of existing products in the fluorescent reagents market.

Strong signals and photostability are extremely important properties as they increase the sensitivity of detection methods and facilitate measurement of the signal, respectively. Increased sensitivity is needed to study disease markers that are present at very low levels--often below those detectable with current technologies. Preliminary testing has shown that the enhanced properties of Priostar dendrimer-dye complexes are retained after attachment to an antibody, an integral component for many of the applications of fluorescent dyes.

The initial commercialization target will be the in vitro diagnostic and research reagent markets. DNT is currently in preliminary commercialization discussions with the market leaders in the area of fluorescence reagents.


Related Links:
Starpharma

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Fetal Monitor
BT-380
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.